Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CNS Pharmaceuticals, Inc. (CNSP : NSDQ)
 
 • Company Description   
CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is based in Houston, United States.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.91 Daily Weekly Monthly
20 Day Moving Average: 160,911 shares
Shares Outstanding: 5.46 (millions)
Market Capitalization: $4.96 (millions)
Beta: 2.58
52 Week High: $4.60
52 Week Low: $0.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.97% -1.85%
12 Week 10.67% -6.91%
Year To Date -84.93% -85.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2100 WEST LOOP SOUTH SUITE 900
-
HOUSTON,TX 77027
USA
ph: 800-946-9185
fax: -
ir@cnspharma.com http://www.cnspharma.com
 
 • General Corporate Information   
Officers
John Climaco - Chief Executive Officer; President and Director
Christopher Downs - Chief Financial Officer
Faith Charles - Director
Jerzy (George) Gumulka - Director
Jeffry Keyes - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 18978H409
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 5.46
Most Recent Split Date: 2.00 (0.02:1)
Beta: 2.58
Market Capitalization: $4.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.24
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 99.85%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -385.41
12/31/24 - -7,392.04
ROA
06/30/25 - -
03/31/25 - -193.20
12/31/24 - -293.64
Current Ratio
06/30/25 - -
03/31/25 - 4.94
12/31/24 - 3.43
Quick Ratio
06/30/25 - -
03/31/25 - 4.94
12/31/24 - 3.43
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 3.73
12/31/24 - 5.37
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©